UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
faldaprevir (32) 32
humans (21) 21
life sciences & biomedicine (21) 21
science & technology (21) 21
simeprevir (19) 19
hepatitis c (18) 18
antiviral agents - therapeutic use (16) 16
sofosbuvir (16) 16
hepatitis c virus (15) 15
ribavirin (14) 14
daclatasvir (13) 13
gastroenterology & hepatology (12) 12
hepacivirus - genetics (12) 12
boceprevir (11) 11
hepacivirus - drug effects (11) 11
hepatitis c, chronic - drug therapy (11) 11
telaprevir (11) 11
antiviral agents - adverse effects (9) 9
genotype (9) 9
protease inhibitors (9) 9
clinical trials as topic (8) 8
hepatitis c - drug therapy (8) 8
oligopeptides - therapeutic use (8) 8
thiazoles - therapeutic use (8) 8
treatment outcome (8) 8
antiviral agents (7) 7
biological response modifiers (7) 7
care and treatment (7) 7
female (7) 7
hiv (7) 7
infectious diseases (7) 7
male (7) 7
middle aged (7) 7
proteases (7) 7
viral nonstructural proteins - antagonists & inhibitors (7) 7
adult (6) 6
asunaprevir (6) 6
drug therapy, combination (6) 6
drug therapy, combination - methods (6) 6
health aspects (6) 6
polyethylene glycols - therapeutic use (6) 6
ribavirin - therapeutic use (6) 6
hepatitis (5) 5
interferon (5) 5
interferon-alpha - therapeutic use (5) 5
pharmacology & pharmacy (5) 5
uridine monophosphate - analogs & derivatives (5) 5
antiviral agents - administration & dosage (4) 4
antiviral agents - pharmacokinetics (4) 4
antiviral agents - pharmacology (4) 4
hepatitis c, chronic - virology (4) 4
heterocyclic compounds, 3-ring (4) 4
medicine & public health (4) 4
oligopeptides (4) 4
oligopeptides - adverse effects (4) 4
oligopeptides - pharmacokinetics (4) 4
pegylated interferon (4) 4
recombinant proteins - therapeutic use (4) 4
sulfonamides (4) 4
thiazoles (4) 4
thiazoles - adverse effects (4) 4
thiazoles - pharmacokinetics (4) 4
antiviral agents - chemistry (3) 3
coinfection (3) 3
danoprevir (3) 3
direct-acting antivirals (3) 3
drug design (3) 3
drug interactions (3) 3
drug therapy (3) 3
genetic aspects (3) 3
genotype 1 (3) 3
healthy volunteers (3) 3
hepacivirus - enzymology (3) 3
hepatitis c, chronic - diagnosis (3) 3
hepatology (3) 3
hiv infections - drug therapy (3) 3
interferon-free (3) 3
japanese (3) 3
ledipasvir (3) 3
liver cirrhosis (3) 3
microbiology (3) 3
oligopeptides - administration & dosage (3) 3
protease inhibitors - therapeutic use (3) 3
risk factors (3) 3
sustained virological response (3) 3
thiazoles - administration & dosage (3) 3
time factors (3) 3
viruses (3) 3
young adult (3) 3
administration, oral (2) 2
aged (2) 2
analysis (2) 2
animals (2) 2
antibiotics. antiinfectious agents. antiparasitic agents (2) 2
antiretroviral therapy, highly active (2) 2
antiretrovirals (2) 2
antiviral (2) 2
antiviral therapy (2) 2
articles and commentaries (2) 2
biological and medical sciences (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical infectious diseases, ISSN 1058-4838, 4/2014, Volume 58, Issue 7, pp. 928 - 936
Antiretrovirals | HIV | Cost estimates | Antivirals | Raw material costs | Raw materials | ARTICLES AND COMMENTARIES | Hepatitis C | Dosage | Hepacivirus | Production costs | sofosbuvir | faldaprevir | ribavirin | simeprevir | daclatasvir | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Antiviral agents | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Heterocyclic Compounds, 3-Ring - economics | Simeprevir | Oligopeptides - economics | Hepatitis C - drug therapy | Ribavirin - economics | Humans | Imidazoles - chemistry | Uridine Monophosphate - chemistry | Uridine Monophosphate - economics | Thiazoles - therapeutic use | Health Services Accessibility - economics | Oligopeptides - therapeutic use | Antiviral Agents - chemistry | Drug Industry - economics | Imidazoles - therapeutic use | Drug Therapy, Combination | Oligopeptides - chemistry | Thiazoles - economics | Uridine Monophosphate - therapeutic use | Sulfonamides - chemistry | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Ribavirin - chemistry | Anti-HIV Agents - chemistry | Sulfonamides - therapeutic use | Imidazoles - economics | Heterocyclic Compounds, 3-Ring - chemistry | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Thiazoles - chemistry | Developing Countries | Antiviral Agents - economics | Sofosbuvir | Economic aspects | Production management | Care and treatment | Hepatitis | Antiviral drugs | Medical treatment | Developing countries--LDCs | Index Medicus | and Commentaries
Journal Article
Journal Article
Journal of clinical pharmacology, ISSN 0091-2700, 10/2017, Volume 57, Issue 10, pp. 1305 - 1314
Journal Article